Advancing gene and cell therapy: Key takeaways from ESGCT 2024

gene and cell therapy

Image Credit: Christopher Burgstedt/Shutterstock.com

Experts from Cerba Research, a leading specialty laboratory solutions provider, recently attended the 31st European Society of Gene and Cell Therapy (ESGCT) Congress to share some of its most recent cell and gene therapy developments with an audience of industry experts, academia, sponsors and patient organizations. Each year, the ESGCT conference attracts key opinion leaders in gene and cell therapy from Europe and around the world, spotlighting recent breakthroughs and advancements in the field and highlighting novel techniques that are moving toward safe and curative treatments for both major and rare diseases. Events such as the ESGCT play a key role in helping to advance, improve and launch these novel treatments into clinical practice, as well as ensuring that cell and gene therapies are safe and effective.

Download the full article

Karthikeyan Devaraju, PhD Sr Scientist Cell & Gene Therapy Development

Picture of Karthikeyan Devaraju

Karthikeyan Devaraju has over 15 years’ experience in the regenerative medicine and advanced therapies (diverse cell and gene therapies). His expertise spans stem cells, cell fate engineering, gene delivery systems, product development and both process and analytical development / optimization using diverse technology platforms. He received his PhD in Stem Cells and Neurology from Lund University. He has held various scientific positions in academic research institutions, bio-pharma and CDMOs.

About Cerba Research

Cerba Research is a leading specialty laboratory services provider with the capacity and breadth of a global central laboratory network. Our highly qualified scientists provide insight on the latest biomarkers, assays and testing approaches and develop innovative solutions for unique challenges across all research phases, to pharmaceutical, biotechnology, medical device, government, public health, and CRO organizations. Cerba Research’s extensive capability in laboratory testing and global logistics including Cell & Gene Therapy, Bioanalysis, Flow Cytometry, HistoCytopathology, and Next Generation Sequencing, enables us to drive operational agility at scale in a wide range of therapeutic areas, with recognized expertise in Virology, Immunology, Oncology and Cell & Gene Therapy. Cerba Research is part of the Cerba HealthCare Group with 15,000 employees on five continents, driven to advance diagnosis and health.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Nov 28, 2024 at 10:40 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cerba Research. (2024, November 28). Advancing gene and cell therapy: Key takeaways from ESGCT 2024. News-Medical. Retrieved on December 06, 2024 from https://www.news-medical.net/whitepaper/20241122/Advancing-gene-and-cell-therapy-Key-takeaways-from-ESGCT-2024.aspx.

  • MLA

    Cerba Research. "Advancing gene and cell therapy: Key takeaways from ESGCT 2024". News-Medical. 06 December 2024. <https://www.news-medical.net/whitepaper/20241122/Advancing-gene-and-cell-therapy-Key-takeaways-from-ESGCT-2024.aspx>.

  • Chicago

    Cerba Research. "Advancing gene and cell therapy: Key takeaways from ESGCT 2024". News-Medical. https://www.news-medical.net/whitepaper/20241122/Advancing-gene-and-cell-therapy-Key-takeaways-from-ESGCT-2024.aspx. (accessed December 06, 2024).

  • Harvard

    Cerba Research. 2024. Advancing gene and cell therapy: Key takeaways from ESGCT 2024. News-Medical, viewed 06 December 2024, https://www.news-medical.net/whitepaper/20241122/Advancing-gene-and-cell-therapy-Key-takeaways-from-ESGCT-2024.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.